An­ti-ag­ing start­up Ele­vian en­lists In­sil­i­co on AI quest for 'y­oung blood'

Some of the ear­li­est con­nec­tions Alex Zha­voronkov has built for his AI shop at In­sil­i­co Med­i­cine in­volves mar­ry­ing an­ti-ag­ing and AI re­search, two of the buzzi­est ar­eas in drug de­vel­op­ment. He’s now dou­bling down on it with a new R&D part­ner­ship with “young blood” start­up Ele­vian.

The col­lab­o­ra­tion is aimed at de­vel­op­ing oral med­ica­tions tar­get­ing the GDF11, or growth dif­fer­en­ti­a­tion fac­tor 11, path­way and as­so­ci­at­ed tar­gets — a con­cept that Ele­vian has been work­ing on since in­cep­tion. Ele­vian is sup­ply­ing the bi­o­log­i­cal and struc­tur­al tar­get da­ta that In­sil­i­co will use to iden­ti­fy small mol­e­cules via its gen­er­a­tive ad­ver­sar­i­al net­works (GANs) and re­in­force­ment learn­ing (RL) AI tech­nolo­gies.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER